Scarica l'app Stockscreener
2.54
0.79%
0.02
Dopo l'orario di chiusura:
2.59
0.05
+1.97%
Cervomed Inc Borsa (CRVO) Ultime notizie
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference - The Manila Times
A neuroscience panel in New York will include CervoMed management Sept. 29 - Stock Titan
CervoMed (CRVO) Rallies +1.02% as Bulls Target $2.60 2026-09-16Turnaround Stocks - careplusvn.com
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally - Stocktwits
CervoMed at Cantor healthcare conference: phase iii path in focus By Investing.com - Investing.com Canada
CervoMed at Cantor healthcare conference: phase iii path in focus - Investing.com India
CRVO: Phase III-ready DLB therapy neflamapimod shows strong efficacy and biomarker support - TradingView
Cervomed Inc (CRVO-Q) Stock Price and News - The Globe and Mail
CervoMed highlights late-breaking neflamapimod Phase 2a data - TipRanks
CervoMed (NASDAQ: CRVO) data accepted for late-breaking dementia conference talk - Stock Titan
CervoMed to present nfvPPA trial biomarker data at ISFTD meeting By Investing.com - Investing.com Nigeria
CervoMed to present neflamapimod trial data at ISFTD - grafa.com
CervoMed to present nfvPPA trial biomarker data at ISFTD meeting - Investing.com
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026 - The Manila Times
No approved treatments exist in the U.S. or EU for this dementia type. CervoMed will present trial data. - Stock Titan
CervoMed's neflamapimod wins UK ILAP Innovation Passport for DLB - scanx.trade
CervoMed to Participate in September Investor Conferences - Yahoo! Finance Canada
Price to earnings forward of CervoMed Inc. – NASDAQ:CRVO - TradingView
CRVO News | CERVOMED INC (NASDAQ:CRVO) - ChartMill
CervoMed (CRVO) Edges Lower to $2.62 as Shares Press Against Heavy SupportBPI Reversal - dars.gov.et
CervoMed Company Profile & Introduction - Moomoo
Hedge Fund Armistice Sues Drugmaker, Insiders for Stock Dilution - Bloomberg Law News
CervoMed (CRVO) Results Review: EPS Exceeds Its Estimate in the Latest Session; Price Reaction - dars.gov.et
ARMISTICE CAPITAL, LLC Acquires New Stake in CervoMed Inc (CRVO) - GuruFocus
Roth MKM Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
SABBY MANAGEMENT, LLC's CervoMed Inc(CRVO) Holding History - GuruFocus
CRVO Q2 2026 Earnings: Loss Narrows 27.7% vs Estimates, Shares Dip 6.8%Earnings Cycle Outlook - vinanet.vn
CervoMed (CRVO): RA Capital discloses 8.6% stake through 1.27M warrant shares - Stock Titan
CervoMed (CRVO) holders CVI and Heights report 0% stake in amended filing - Stock Titan
Woodline Partners (CRVO) discloses 5.1% beneficial stake in CervoMed common stock - Stock Titan
Armistice Capital discloses 9.53% CervoMed (CRVO) ownership via Master Fund - Stock Titan
CRVO Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.64 Beats Estimates by 27.7%; Shares Slip 4.56% - vinanet.vn
CRVO Reiterates by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $18 - Moomoo
CervoMed at Canaccord Genuity conference: dLB push gains ground By Investing.com - Investing.com Nigeria
CRVO: Phase III-ready DLB drug shows strong clinical data; pipeline expands into PPA and ALS - TradingView
CervoMed at Canaccord Genuity conference: dLB push gains ground - Investing.com
CervoMed Inc. (CRVO) Surges 9% as Biotech Stock Approaches Key Resistance at $3.28Stop Loss Guidance - dars.gov.et
JonesTrading Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
CervoMed reports Q2 2026: $24.9M cash position, net loss $6.6M; advancing neflamapimod toward Phase 3 - TradingView
CervoMed (NASDAQ: CRVO) details Q2 2026 loss, cash runway and DLB program - Stock Titan
Canaccord cuts CervoMed stock price target on funding uncertainty By Investing.com - Investing.com India
CervoMed presents data on DLB treatment at AAIC 2026 - scanx.trade
CRVO Maintained by Canaccord Genuity -- Price Target Lowered to $18 - GuruFocus
CervoMed Q2 Results: EPS Misses Estimate, Losses Widen YoY - scanx.trade
CervoMed Q2 Results: Net Loss Widens To $6.6M, Seeks DLB Partner - scanx.trade
Canaccord cuts CervoMed stock price target on funding uncertainty - Investing.com
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times
CervoMed Q2 net loss lower than estimates as costs drop - TradingView
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $18 - Moomoo
CRVO Q2'26 Earnings: revenue estimate is 50.00K USD - TradingView
CERVOMED INC : CANACCORD GENUITY CUTS TARGET PRICE TO $18 FROM $27 - Bitget
CervoMed (NASDAQ:CRVO) Will Have To Spend Its Cash Wisely - simplywall.st
CervoMed Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CervoMed Inc. 2026: Revenue $0 Net income ($6.57M), EPS ($0.64) — 10-Q Summary - TradingView
CRVO: Raised $20.5M in June 2026 to fund R&D and strategic partnership for Phase 3 DLB trial - TradingView
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):